Skip to main content
. 2019 Nov 23;11(12):1854. doi: 10.3390/cancers11121854

Figure 4.

Figure 4

DFS survival curves for ATG4B and phospho-Ser383/392-ATG4B expression in patients with BMSCC or TSCC. (A) DFS survival curves in relation to ATG4B or (B) phospho-Ser383/392-ATG4B (pATG4B) expression are shown for OSCC (left panel), BMSCC (middle), and TSCC (right panel) patients. (C) DFS survival curves for the coexpression of ATG4B and phospho-Ser383/392-ATG4B are shown for OSCC, BMSCC, and TSCC patients. The cutoff values for high or low protein levels of ATG4B and phospho-Ser383/392-ATG4B in tumor tissues were based on the ROC curve.